AU2002346562A1 - Method for treating ocular hypertension - Google Patents

Method for treating ocular hypertension Download PDF

Info

Publication number
AU2002346562A1
AU2002346562A1 AU2002346562A AU2002346562A AU2002346562A1 AU 2002346562 A1 AU2002346562 A1 AU 2002346562A1 AU 2002346562 A AU2002346562 A AU 2002346562A AU 2002346562 A AU2002346562 A AU 2002346562A AU 2002346562 A1 AU2002346562 A1 AU 2002346562A1
Authority
AU
Australia
Prior art keywords
alkyl
phenyl
alkyloxy
hydroxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002346562A
Other languages
English (en)
Inventor
Xavier Billot
Kathleen M Metters
Miller J Ogidigben
Deborah M Slipetz
Robert N Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Merck and Co Inc
Original Assignee
Merck Frosst Canada Ltd
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd, Merck and Co Inc filed Critical Merck Frosst Canada Ltd
Publication of AU2002346562A1 publication Critical patent/AU2002346562A1/en
Assigned to MERCK FROSST CANADA LTD., MERCK & CO., INC. reassignment MERCK FROSST CANADA LTD. Request for Assignment Assignors: MERCK & CO., INC., MERCK FROSST CANADA & CO.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002346562A 2001-12-03 2002-11-27 Method for treating ocular hypertension Abandoned AU2002346562A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33811701P 2001-12-03 2001-12-03
US60/338,117 2001-12-03
US40050402P 2002-08-02 2002-08-02
US60/400,504 2002-08-02
PCT/US2002/038040 WO2003047513A2 (en) 2001-12-03 2002-11-27 Method for treating ocular hypertension

Publications (1)

Publication Number Publication Date
AU2002346562A1 true AU2002346562A1 (en) 2003-06-17

Family

ID=26991044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002346562A Abandoned AU2002346562A1 (en) 2001-12-03 2002-11-27 Method for treating ocular hypertension

Country Status (5)

Country Link
EP (1) EP1461026A2 (https=)
JP (1) JP2005514378A (https=)
AU (1) AU2002346562A1 (https=)
CA (1) CA2466757A1 (https=)
WO (1) WO2003047513A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7872045B2 (en) * 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
EP1461026A2 (en) * 2001-12-03 2004-09-29 Merck & Co., Inc. Method for treating ocular hypertension
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
US7256211B1 (en) 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
US7235586B2 (en) * 2003-09-09 2007-06-26 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
ATE550323T1 (de) 2004-06-04 2012-04-15 Allergan Inc Piperidinyl-prostaglandinanaloga als den augeninnendruck senkende mittel
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US8013159B2 (en) 2005-05-19 2011-09-06 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
WO2008058766A1 (en) 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
WO2011047048A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2014015247A1 (en) * 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
PT2989098T (pt) 2013-03-15 2017-08-16 Cayman Chemical Co Inc Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4
CA2903314C (en) 2013-03-15 2023-02-14 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
KR20160048054A (ko) 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1461026A2 (en) * 2001-12-03 2004-09-29 Merck & Co., Inc. Method for treating ocular hypertension
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
WO2003047513A3 (en) 2004-07-15
WO2003047513A2 (en) 2003-06-12
EP1461026A2 (en) 2004-09-29
CA2466757A1 (en) 2003-06-12
JP2005514378A (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
AU2002346562A1 (en) Method for treating ocular hypertension
JP4866992B2 (ja) Ｅｐ４受容体作動薬としてのプロスタグランジン類縁体
US20090258918A1 (en) EP4 receptor agonist, compositions and methods thereof
JP2006504679A (ja) 緑内障の治療においてｅｐ４受容体作動薬として使用するためのオキサゾリジン−２−オンおよびチアゾリジン−２−オン誘導体
WO2003097596A1 (en) 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2002346561B2 (en) EP4 receptor agonist, compositions and methods thereof
US20060167081A1 (en) Ep4 receptor agonists
JP2005534653A (ja) 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
US20040254230A1 (en) Method for treating ocular hypertension
US20090105234A1 (en) EP4 Receptor Agonist, Compositions and Methods Thereof
AU2004245492B2 (en) 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
ES2354516T3 (es) Derivados de pirrolid-2-ona 1,5-disustituida para su uso como agonista del receptor de ep4 en el tratamiento de enfermedades oculares tales como glaucoma.
AU2011202937B2 (en) 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MERCK & CO., INC.; MERCK FROSST CANADA LTD.

Free format text: FORMER APPLICANT(S): MERCK & CO., INC.; MERCK FROSST CANADA & CO.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted